Dementia risk with antihypertensive use and blood pressure variability A cohort study

被引:37
|
作者
Tully, Phillip J. [1 ,3 ,7 ]
Dartigues, Jean-Francois [2 ]
Debette, Stephanie [1 ,4 ,5 ]
Helmer, Catherine [2 ]
Artero, Sylvaine [6 ]
Tzourio, Christophe [1 ,7 ]
机构
[1] Univ Bordeaux, Neuroepidemiol, UMR897, Bordeaux, France
[2] Univ Bordeaux, Epidemiol & Biostat, INSERM, U897, Bordeaux, France
[3] Univ Adelaide, Freemasons Fdn Ctr Mens Hlth, Sch Med, Discipline Med, Adelaide, SA 5005, Australia
[4] Bordeaux Univ Hosp, Dept Neurol, Bordeaux, France
[5] Boston Univ, Sch Med, Framingham Heart Study, Dept Neurol, Boston, MA 02215 USA
[6] Univ Montpellier I, La Colombiere Hosp, INSERM, U1061, F-34006 Montpellier, France
[7] INSERM, Neuroepidemiol, UMR897, Bordeaux, France
关键词
ANGIOTENSIN RECEPTOR BLOCKERS; TO-VISIT VARIABILITY; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; INCIDENT DEMENTIA; GINKGO EVALUATION; REDUCED RISK; OLDER-ADULTS; DRUG-USE; ASSOCIATION;
D O I
10.1212/WNL.0000000000002946
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To determine the association between discrete antihypertensive drug classes and incident dementia controlling for blood pressure variability (BPV) in the preceding 4 years. Methods: A total of 6,537 participants (mean age 79 years, 62% women) in a prospective population-based cohort were followed up for incident dementia. A 4-year time lag period was created to classify drug exposure and measure blood pressure. BPV (percent coefficient of variation [CV]) was regressed against 9 antihypertensive drug classes (BPVreg). Cox regression models were employed to determine hazard ratios (HRs) for incident dementia thereafter according to drug class, adjusted for mean blood pressure, covariates, and BPV or BPVreg. Results: Over a median 8.4 years follow-up (interquartile range 6.7-9.0), lower dementia risk was associated with nondihydropyridine calcium channel blocker (HR 0.56; 95% confidence interval [CI] 0.31-1.00, p = 0.05) and loop diuretics (HR 0.45; 95% CI 0.22-0.93, p=0.03) after adjusting for CV-BPV. Similar findings were obtained in analyses restricted to antihypertensive drug users for nondihydropyridine calcium channel blocker (HR 0.52; 95% CI 0.28-0.95, p=0.03) and loop diuretics (HR 0.40; 95% CI 0.19-0.83, p=0.01). All systolic BPV 3 antihypertensive drug interaction terms were not different from p, 0.05. Conclusions: Nondihydropyridine calcium channel blocker and loop diuretics were associated with a reduced dementia risk independent of CV-BPV in the preceding 4 years. Systolic BPV was not the primary mechanism through which antihypertensive drug classes lower dementia risk.
引用
收藏
页码:601 / 608
页数:8
相关论文
共 50 条
  • [41] Fasting Glucose Variability and the Risk of Dementia in Individuals with Diabetes: A Nationwide Cohort Study
    Lee, Da Young
    Kim, Jaeyoung
    Park, Sanghyun
    Park, So Young
    Yu, Ji Hee
    Seo, Ji A.
    Kim, Nam Hoon
    Yoo, Hye Jin
    Kim, Sin Gon
    Choi, Kyung Mook
    Baik, Sei Hyun
    Han, Kyungdo
    Kim, Nan Hee
    DIABETES & METABOLISM JOURNAL, 2022, 46 (06) : 923 - 935
  • [42] Antihypertensive Treatment and Short-Term Blood Pressure Variability
    De La Sierra, Alejandro
    Banegas, Jose R.
    de la Cruz, Juan J.
    Gorostidi, Manuel
    Vinyoles, Ernest
    Segura, Julian
    Ruilope, Luis M.
    HYPERTENSION, 2019, 74
  • [43] Antihypertensive Medication and Dementia Risk in Older Adult African Americans with Hypertension: A Prospective Cohort Study
    Murray, Michael D.
    Hendrie, Hugh C.
    Lane, Kathleen A.
    Zheng, Mengjie
    Ambuehl, Roberta
    Li, Shanshan
    Unverzagt, Frederick W.
    Callahan, Christopher M.
    Gao, Sujuan
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2018, 33 (04) : 455 - 462
  • [44] Antihypertensive Medication and Dementia Risk in Older Adult African Americans with Hypertension: A Prospective Cohort Study
    Michael D. Murray
    Hugh C. Hendrie
    Kathleen A. Lane
    Mengjie Zheng
    Roberta Ambuehl
    Shanshan Li
    Frederick W. Unverzagt
    Christopher M. Callahan
    Sujuan Gao
    Journal of General Internal Medicine, 2018, 33 : 455 - 462
  • [45] Effect of antihypertensive treatment with telmisartan or lercanidipine on blood pressure variability
    Crippa, G
    Giorgi-Pierfranceschi, M
    Venturi, C
    Sverzellati, E
    AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (05) : 103A - 103A
  • [46] Blood pressure variability, target organ damage and antihypertensive treatment
    Parati, G
    JOURNAL OF HYPERTENSION, 2003, 21 (10) : 1827 - 1830
  • [47] Blood pressure and risk of incident Alzheimer's disease dementia by antihypertensive medications and APOE ε4 allele
    Rajan, Kumar B.
    Barnes, Lisa L.
    Wilson, Robert S.
    Weuve, Jennifer
    McAninch, Elizabeth A.
    Evans, Denis A.
    ANNALS OF NEUROLOGY, 2018, 83 (05) : 935 - 944
  • [48] Blood Pressure and Risk of Dementia in a Cohort of 2.6 Million People Over Two Decades
    Qizilbash, Nawab
    Gregson, John
    Johnson, Michelle E.
    Pearce, Neil
    Douglas, Ian
    Wing, Kevin
    Pocock, Stuart J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 105 - 105
  • [49] Day-to-day blood pressure variability and dementia
    Ohara, Tomoyuki
    Oishi, Emi
    Ninomiya, Toshiharu
    ONCOTARGET, 2017, 8 (70) : 114416 - 114417
  • [50] Visit-to-visit blood pressure variability and dementia
    Nagai, Michiaki
    Hoshide, Satoshi
    Dote, Keigo
    Kario, Kazuomi
    GERIATRICS & GERONTOLOGY INTERNATIONAL, 2015, 15 : 26 - 33